Safety, Tolerability and Pharmacokinetics of Intravenous Sodium Taurodeoxycholate, HY209, a GPCR19 Agonist Inhibiting Inflammasomal Activation
A single intravenous administration of HY209 was well tolerated and its systemic exposure showed dose-proportionality in a dose range between 0.1 and 1.6 mg/kg.
Authors
- Woo Kyung Chung (ORCID: https://orcid.org/0000-0002-3411-7421)
- Seung‐Yong Seong (ORCID: https://orcid.org/0000-0002-3671-1029)
- In‐Jin Jang (ORCID: https://orcid.org/0000-0002-8384-3139)
- Kyung‐Sang Yu (ORCID: https://orcid.org/0000-0003-0921-7225)
- Inseung Jeon (ORCID: https://orcid.org/0000-0002-4035-1230)
- Sang-Sup Han
Institutions
- Seoul National University (KR)
- Seoul National University Hospital (KR)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/dddt.s438507
- Citations
- 3
- Primary Topic
- Apelin-related biomedical research
- Type
- article
- Field-Weighted Citation Impact
- 1.34